| Product Name | CTXI ELISA kit (Rat) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Cross Linked C-Telopeptide Of Type I Collagen (CTXI). No significant cross-reactivity or interference between Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and analogues was observed. |
| Synonyms | CTX-I; CTX1; |
| Method | Competitive |
| Detection Range | 123.5-10,000pg/mL |
| Sensitivity | 45.3pg/mL |
| Target | CTXI |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Cross Linked C-Telopeptide Of Type I Collagen (CTXI). No significant cross-reactivity or interference between Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and analogues was observed. |
| Reactivity | Rat |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats;Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway;The RIP1–RIP3 Complex Mediates Osteocyte Necroptosis after Ovariectomy in Rats;Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway;The effect of lamotrigine and phenytoin on bone turnover and bone strength: A prospective study in Wistar rats;Effects of long-term administration of pantoprazole on bone mineral density in young male rats.;Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats;Side-Effects of Convulsive Seizures and Anti-Seizure Therapy on Bone in a Rat Model of Epilepsy;The role of androgens on periodontal repair in female rats;Myricetin ameliorates glucocorticoid-induced osteoporosis through the ERK signaling pathway;The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolism;Effects of Amlodipine on Bone Metabolism in Orchidectomised Spontaneously Hypertensive Rats;Mollugin attenuates glucocorticoid-induced osteoporosis in rats via Akt/P13K pathway;Influence of physical training on markers of bone turnover, mechanical properties, morphological alterations, density and mineral contents in the femur of rats exposed …;E The Effects of Ficus Carica Fruit on Bone Markers and Oestrogen Level of Post-Menopausal Osteoporotic Rats;Role of testosterone and androgen receptor in periodontal disease progression in female rats;Alleviating Effect of α-Lipoic Acid and Magnesium on Cadmium-Induced Inflammatory Processes, Oxidative Stress and Bone Metabolism Disorders in Wistar Rats;Beneficial effects of Cuscuta chinensis extract on glucocorticoid-induced osteoporosis through modulation of RANKL/OPG signals;The Effects of Ficus Carica Fruit on Bone Markers and Oestrogen Level of Post-Menopausal Osteoporotic Rats.;Qu Feng Zhi Tong capsule increases mechanical properties of cortical bone in ovariectomized rats;The Effects of Ficus Carica Fruit on Bone Markers and Oestrogen Level of Post-Menopausal Osteoporotic Rats;;A biomimetically hierarchical polyetherketoneketone scaffold for osteoporotic bone repair;Effects of icariin on the fracture healing in young and old rats and its mechanism;Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway;Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy;Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles;Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway; |
| Supplier | Cloud Clone |
PROTOCOLS:
CEA665Ra All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
